Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPACT: Phase 0 WOO in Ovarian Cancer
NCT03378297Phase 1Completed
- Sponsor
- Haukeland University Hospital
- Start
- May 2018
- Primary completion
- Jan 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liquid metformin (Aspargo Labs), aspirin, olaparib and letrozole in ovarian cancer (5 arms), sponsored by Haukeland University Hospital. Primary endpoint: Changes in the expression of biomarkers at 3 months. Started May 2018; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)aspirinolaparibletrozole
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03378297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03378297.